3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

One of my investment themes, as I look for structural changes tied to the evolving economic, demographic, technological and psychographic landscapes, is the Aging of the Population. It’s no secret that several countries are experiencing a demographic shift in their populations that skews older. Here in the U.S., the first baby boomers started turning 70 in 2016, but in the coming years, the percentage of the U.S. population that is 65 years or older will explode.

By 2030, all baby boomers will be older than age 65. This will expand the size of the older population so that one in every five residents will be retirement age. At the same time, we are living longer, with the most recent data published by the Census Bureau showing average U.S. life expectancy rose to 78.6 years in 2017, up from 68 years in 1950. According to data published by Care Patrol, which focuses on safer senior living, by 2020 roughly 15 million of the elderly population in the U.S. will have some form of disability and by 2030, “more than 6 of every 10 boomers will manage more than one chronic condition.”

More people living longer is a development that will give rise to greater and in some ways different demands…

Read more here 

About the Author

Chris Versace, Chief Investment Officer
I'm the Chief Investment Officer of Tematica Research and editor of Tematica Investing newsletter. All of that capitalizes on my near 20 years in the investment industry, nearly all of it breaking down industries and recommending stocks. In that time, I've been ranked an All Star Analyst by Zacks Investment Research and my efforts in analyzing industries, companies and equities have been recognized by both Institutional Investor and Thomson Reuters’ StarMine Monitor. In my travels, I've covered cyclicals, tech and more, which gives me a different vantage point, one that uses not only an ecosystem or food chain perspective, but one that also examines demographics, economics, psychographics and more when formulating my investment views. The question I most often get is "Are you related to…."

Comments are closed.